Table 3.

In vitro MICs (μg/ml) of MN 2(6), Van, Rif, AmB against various bacterial pathogens and fungal pathogens by broth dilution method.

Organism	MN 2(6)	Van	Rif	AmB
S. aureus MTCC 2940	1	2	4	NA
S. aureus MTCC 96	2	0.5	0.5	NA
S. aureus clinical-1 (β-lactamase)	2	1	0.5	NA
S. aureus clinical-2 (β-lactamase)	5	1	0.25	NA
S. aureus clinical-3 (β-lactamase)	5	1	0.12	NA
B. subtilis MTCC 441	5	4	2	NA
M. luteus MTCC 106	5	4	0.01	NA
E. coli MTCC 739	25	–	64	NA
E. coli MTCC 2939	5	–	1	NA
E. coli clinical	50	–	16	NA
P. aeruginosa MTCC 424	512	–	64	NA
P. aeruginosa clinical-1	512	–	128	NA
P. aeruginosa clinical-2	512	–	64	NA
Salmonella sp.	512	512	32	NA
Acinetobacter junii MTCC 1686	0.5	1	0.03	NA
Acinetobacter baumanii MTCC 1425	1	256	8	NA
E. faecalis MTCC 439	2	1	4	NA
M. smegmatis MTCC 6	0.25	16	8	NA
Candida parapsilosis	2			2
Candida albicans MTCC 1637	2			1
Candida tropicalis MTCC 2208	2			2.5

Product of Streptomyces sp. MN 2(6); Van, vancomycin sulfate; Rif, rifampicin; AmB, amphotericin-B, –, not active; NA, not applicable.